Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-036861
Filing Date
2025-07-31
Accepted
2025-07-31 08:57:58
Documents
88
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q vnda-20250630.htm   iXBRL 10-Q 1090803
2 EX-10.1 vnda6302025ex101.htm EX-10.1 59422
3 EX-31.1 vndaex311630202510q.htm EX-31.1 10319
4 EX-31.2 vndaex312630202510q.htm EX-31.2 9953
5 EX-32.1 vndaex321630202510q.htm EX-32.1 6583
11 vnda6302025ex101image.jpg GRAPHIC 46795
  Complete submission text file 0001628280-25-036861.txt   6385589

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20250630.xsd EX-101.SCH 50819
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20250630_cal.xml EX-101.CAL 69515
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20250630_def.xml EX-101.DEF 211028
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20250630_lab.xml EX-101.LAB 590923
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20250630_pre.xml EX-101.PRE 432076
91 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20250630_htm.xml XML 805800
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 251169655
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)